Leading the Way in

Pancreatic Cancer Diagnostics

Immunovia’s mission is to save lives through early detection of pancreatic cancer.

Pancreatic cancer
—a cruel, lethal killer

Pancreatic cancer is the deadliest major cancer, with a five-year survival rate of just 13%. Why? Pancreatic cancer is often diagnosed too late: Four out of five people are not diagnosed until their cancer has spread beyond the pancreas. Just 3% of people diagnosed at Stage 3 or 4 survive to five years.

Annual surveillance is crucial for people at risk

Many people are at high risk for pancreatic cancer because of family history or genetic mutations. For these high-risk individuals, annual surveillance is crucial. Today that means inconvenient or even invasive annual imaging tests like endoscopic ultrasound or MRI. An accurate, convenient blood test to detect pancreatic cancer is needed.

Early detection offers hope

Early detection can make the difference. The odds of survival for people diagnosed at Stage 1 and 2 are more than 10X higher.

The PancreaSure test
— Accurate, simple, convenient

PancreaSure is a simple blood test proven to detect pancreatic cancer at stage 1 and 2 with high accuracy. It’s for people at elevated risk for pancreatic cancer due to family history or genetic mutations. PancreaSure detects proteins and other biomarkers of pancreatic cancer growth.

shutterstock_2455466377_redigerad copy

PancreaSure
- Proven Accuracy

In a study of blood samples from 1,066 people, PancreaSure detected early-stage cancer in 78% of cancerous samples. PancreaSure also showed specificity of 94%, avoiding false positive results in nearly 19 out of 20 blood samples from people without cancer.

Immunovia

Early Detection.
Better Outcomes.

We are passionate about revolutionizing pancreatic cancer detection. Founded and headquartered in Sweden, today Immunovia’s focus is on the US, the first market where the PancreaSure test will be launched

Press releases

News and updates

Next event

Contact
Get in touch with us
Shopping Basket